Anti-TNFRSF8 therapeutic antibody (Pre-made Brentuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-080-1mg	1mg	Inquiry
GMP-Bios-ab-080-10mg	10mg	Inquiry
GMP-Bios-ab-080-100mg	100mg	Inquiry
GMP-Bios-ab-080-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-TNFRSF8 therapeutic antibody (Pre-made Brentuximab biosimilar,Whole mAb ADC)
INN Name	Brentuximab
Target	TNFRSF8
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine
Conditions Approved	Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma
Conditions Active	Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma
Conditions Discontinued	Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus
Development Tech	na